Alyra Therapeutics
Next-generation precision oncology
Alyra Therapeutics
Next-generation precision oncology
Next-generation precision oncology
Next-generation precision oncology
Headquartered in San Diego, CA with collaborators in Irvine, CA, Austin, TX and Genoa, Italy, we are a team of academic scientists and veteran pharmaceutical industry executives focused on developing novel first-in-class protein-protein interaction inhibitors for the treatment of cancer and rare diseases.
Using an innovative drug discovery platform that integrates computational chemistry and both intracellular and biophysical assay technologies we have identified allosteric inhibitors of the ras-family GTPases RHOJ and CDC42 that block the signaling interaction between these proteins and their respective PAK family protein kinase effectors.
We are focused on our clinical lead compound, ALY101. A highly selective inhibitor of tumor growth and angiogenesis, ALY101 has activity against melanoma tumors in both in vitro and in vivo settings and has demonstrated the potential to impact the treatment of additional cancers as well as multiple rare diseases.
Copyright © 2020 Alyra Therapeutics, Inc. - All Rights Reserved.
Powered by GoDaddy